What smart money is saying about ElectroCore
1 fund in our archive has pitched ElectroCore, most recently Rogue Funds in December 2024.
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Get an email when a fund buys, sells or pitches it
Position history
Every position in ElectroCore on record in the archive was reported in Q4 2024, across 1 fund letter, with 1 sell (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q4 2024 | 1 | 0 | 1 | 1 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 1 position · 1 move
- TrimmedRogue FundsDecember 2024
“ElectroCore I am still very excited about this high growth and high margin business. They hit profitability within the next 6 months while growing revenue at a ~50% consistent CAGR and new devices beginning to scale. Their recent acquisition of NURO (if it gets approved) could be extremely accretive to the company. I have released a few pieces on our blog regarding the company (three now I believe). We trimmed slightly from when we took the position, but it is still a 10%+ position (due to its strong outperformance).”
ElectroCore
Fund coverage · 1 thesis
- Rogue FundsDecember 2024
ElectroCore is a high-growth, high-margin company expected to achieve profitability in the next six months, with significant long-term potential despite short-term challenges from warrant dilution and scaling issues.
Read the full thesis
Read every full thesis on ElectroCore
Read all 1 thesis in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→